Palantir Technologies (NYSE:PLTR – Get Free Report)‘s stock had its “underperform” rating restated by equities research analysts at Royal Bank of Canada in a report issued on Tuesday, Benzinga reports. They presently have a $5.00 target price on the stock. Royal Bank of Canada’s target price indicates a potential downside of 76.09% from the company’s […]
Fidelis Capital Partners LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 31.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,331 shares of the biopharmaceutical company’s stock after selling 2,014 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $251,000 as of its most […]
Milestone Investment Advisors LLC bought a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund bought 467 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Other hedge funds and other institutional investors also recently modified their holdings of the company. SevenBridge Financial Group LLC […]
Mcintyre Freedman & Flynn Investment Advisers Inc. grew its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 14.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,051 shares of the biopharmaceutical company’s stock after buying an additional 1,000 shares […]
Sumitomo Mitsui Financial Group Inc. raised its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 6.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 170,520 shares of the biopharmaceutical company’s stock after buying an additional 10,804 shares during the period. Sumitomo Mitsui Financial Group Inc.’s holdings in Bristol-Myers Squibb were worth $9,897,000 at […]